Medexus Pharmaceuticals

About Medexus Pharmaceuticals

Medexus Pharmaceuticals Inc. operates as a specialty pharmaceutical company with a robust commercial platform across North America, concentrating on underserved niche markets. The current iteration of the company was formed in September 2018 through the amalgamation of three separate entities: Pediapharm Inc., Medexus Inc., and Medac Pharma. This strategic merger created a stronger commercial entity with an expanded portfolio. The company was founded by Ken d'Entremont, who serves as the Chief Executive Officer. His extensive background in the pharmaceutical sector includes a long tenure at Sanofi, where he was Vice President of Business Development and led in-licensing for the Canadian division. This experience in identifying and acquiring promising pharmaceutical assets is central to the company's strategy.

The company's business model is centered on acquiring and licensing specialty pharmaceutical products to commercialize them in the North American market. This strategy leverages its established infrastructure, which includes commercial operations, supply chain management, regulatory affairs, and a dedicated sales force. Medexus generates revenue through the sale of its product portfolio to wholesalers, distributors, government agencies, healthcare facilities, and specialty pharmacies. The company operates through two primary segments: Medexus Pharma Canada and Medexus Pharma USA. This dual-market focus allows for tailored strategies within the distinct healthcare systems of each country.

Medexus's product portfolio addresses needs in hematology, rheumatology, auto-immune diseases, allergy, dermatology, and oncology. Key products include IXINITY, a treatment for hemophilia B; Rasuvo and Metoject, formulations of methotrexate for treating rheumatoid arthritis and other autoimmune diseases; Rupall, a prescription allergy medication; and Gleolan, an imaging agent used in glioma surgery. Another significant product is GRAFAPEX (treosulfan), used as part of a regimen for stem cell transplantation in patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The company actively seeks to grow both organically by enhancing the market performance of existing drugs and through disciplined business development, including new product launches and acquisitions.